Bevacizumab inhibits proliferation of choroidal endothelial cells by regulation of the cell cycle | Zendy

K V Chalam | Zendy; Raluca Rusovici | Zendy; Chirag J. Patel | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Bevacizumab inhibits proliferation of choroidal endothelial cells by regulation of the cell cycle

Author(s) -

K V Chalam,

Raluca Rusovici,

Chirag J. Patel

Publication year - 2013

Publication title -

clinical ophthalmology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.025

H-Index - 56

eISSN - 1177-5483

pISSN - 1177-5467

DOI - 10.2147/opth.s41556

Subject(s) - bevacizumab , propidium iodide , vascular endothelial growth factor , medicine , cell cycle , choroidal neovascularization , macular degeneration , population , flow cytometry , cell growth , ophthalmology , apoptosis , cancer research , biology , immunology , cancer , chemotherapy , vegf receptors , biochemistry , programmed cell death , environmental health

The purpose of this study was to evaluate cell cycle changes in choroidal endothelial cells treated with varying doses of bevacizumab in the presence of a range of concentrations of vascular endothelial growth factor (VEGF). Bevacizumab, a drug widely used in the treatment of neovascular age-related macular degeneration, choroidal neovascularization, and proliferative diabetic retinopathy, neutralizes all isoforms of VEGF. However, the effect of intravitreal administration of bevacizumab on the choroidal endothelial cell cycle has not been established.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research